- Skin Analytics raises £15M in Series B funding led by Intrepid Growth Partners.
- Its AI device, DERM, diagnoses skin cancer with 99.9% accuracy in minutes.
- Deployed across 26 NHS sites, it cuts face-to-face appointments by up to 95%.
Skin Analytics has developed a groundbreaking AI medical device, DERM, that can detect skin cancer within five minutes—without the need for a doctor’s review.
With a £15 million investment from Intrepid Growth Partners, the company plans to expand its reach. It aims to apply its AI technology to a wider range of skin conditions.
AI and Dermatology: How Skin Analytics is Transforming Global Healthcare Access
Founded in 2012, Skin Analytics is addressing a critical bottleneck in skin cancer diagnosis. This is especially crucial in regions with limited access to specialists. The company‘s AI system has already detected over 14,000 cancers. It has also evaluated more than 150,000 NHS patients, making a tangible impact on patient outcomes.
DERM, the company’s flagship device, is the first of its kind to gain legal clearance for autonomous clinical decisions on skin cancer. By removing the need for doctor review, it significantly shortens wait times. It also reduces unnecessary hospital visits.
This innovation comes at a time when healthcare systems globally are grappling with staff shortages and increasing demand. In Europe, the average ratio of dermatologists is only 30 per million people. This highlights the urgent need for scalable solutions like DERM.
The funding led by Intrepid Growth Partners signals strong investor confidence in the power of AI to solve real-world medical challenges. With leaders from global institutions backing Skin Analytics, the company is now positioned to scale its AI-driven impact across borders.
Skin Analytics is setting a new standard for AI in medicine. It demonstrates how machine intelligence can drive both accessibility and accuracy in life-saving diagnostics.
“AI allows us to move from a world of specialist scarcity to one where we have the capacity to see everyone who is concerned about their skin.” – Neil Daly, CEO
